Impact Factor
3.59
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.72
373 total citations
h5-index
20
h5 depth signal
Cited share
80.2%
65 of 81
Total citations
373
Citation footprint
Metric signal
4.96
External metric anchor
Self-citation
1.3%
5 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
215
Canada
18
France
16
Australia
13
United Kingdom
13
Citing Fields of Research
Oncology
185
Breast Cancer
38
Medical Ethics
33
Palliative Care
27
Substance Abuse
23
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
822
Articles tracked across the journal lifetime
Indexed publication set
81
65 cited publications
Last 12 months
20
5.0 publications/month
Open access share
5.0%
1 OA publications in the last year
Leading citing country
United States
215 citing publications
Leading citing field
Oncology
185 citing publications
Latest tracked publication
16 October 2026
10 recent records available
Coverage & Indexing History
n10, 1990-
n10, 1990-
Active Coverage
Research Focus & Classification
Indexed Subjects
Oncology
Nicotine Addiction Treatment
Statistical Methods
Palliative Care
Issuing & Sponsoring Bodies
Contributor
National Cancer Institute (U.S.)
Broad Categories
Neoplasms
Substance Abuse
Oncology
Breast Cancer
Health Education & Remote Healthcare
Medical Ethics
MeSH Descriptors
Neoplasms
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1093/jncimonographs/lgag019
Open DOI
Exemplar 1: Clinical Trials Innovations for Rural Areas
People who reside in rural areas have higher incidence of cancer, limited access to timely high-quality cancer care, and worse survival. Limited clinical trials access for rural residents with cancer exemplifies the challenge of rural ca...
02
DOI 10.1093/jncimonographs/lgag021
Open DOI
Cancer Risk Factors, Screening, and Neighborhood Socioeconomic Deprivation Across the U.S. Urban-to-Frontier Continuum
Background: Rural U.S. populations experience higher cancer burden and lower utilization of preventive services. Heterogeneity within rural areas is poorly characterized, limiting identification of communities with the greatest needs. Me...
03
DOI 10.1093/jncimonographs/lgag020
Open DOI
Non-completion of colorectal cancer screening among Alaska Native people in an intervention trial
Background: The Alaska Tribal Health System is working to increase colorectal cancer (CRC) screening among Alaska Native peoples. It is unknown why people who initially agree might not follow through with screening completion. Methods: A...
04
DOI 10.1093/jncimonographs/lgag018
Open DOI
Correction to: The continuing importance of the IARC’s international remit in cancer research
05
DOI 10.1093/jncimonographs/lgag012
Open DOI
From evidence to practice: leveraging implementation science for transitioning to risk-adapted cervical cancer screening
Population-wide human papillomavirus vaccination has transformed the epidemiology of cervical cancer and accelerated the interest in risk-adapted screening approaches that tailor screening intervals, methods, and triage pathways to an in...
06
DOI 10.1093/jncimonographs/lgag013
Open DOI
How to evaluate and select cervical screening and triage tests in vaccinated populations
The substantial changes of human papillomavirus (HPV) type distribution and reductions of cervical precancer and cancer incidence in vaccinated populations, which are entering screening programs now, require reassessment of screening and...
07
DOI 10.1093/jncimonographs/lgag014
Open DOI
How practically feasible is tailored screening for cervical cancer based on human papillomavirus vaccination status?: the role of data linkage and registers
There is substantial evidence examining effectiveness of human papillomavirus vaccines in populations using registry linkages. These studies initially mapped early outcomes, but in recent years have focused on harder endpoints, confirmin...
08
DOI 10.1093/jncimonographs/lgag015
Open DOI
Developments in human papillomavirus vaccines, schedules, and implementation strategies
Our aspiration is a future with universal administration prior to exposure using simply delivered and affordable vaccines covering all high-risk human papillomavirus (HPV) types and other HPVs associated with significant morbidity. Howev...
09
DOI 10.1093/jncimonographs/lgag011
Open DOI
Evidence for type replacement as a consequence of vaccination and implications for cervical screening
The success of prophylactic human papillomavirus (HPV) vaccination in reducing disease burden came with an epidemiological concern: HPV type replacement, the potential compensatory increase of nonvaccine targeted HPV types following the ...
10
DOI 10.1093/jncimonographs/lgag008
Open DOI
Benefits, harms, and cervical cancer elimination timing of human papillomavirus screening approaches tailored to birth cohort as a proxy for vaccination status in the United States: a comparative modeling study
Screening recommendations in the United States have not been modified for women who have been vaccinated against human papillomavirus (HPV). Using 3 independent Cancer Intervention and Surveillance Modeling Network (CISNET) models (Polic...
Bibliographical & Catalog Notes
Also issued online.
No. 15 (1993)19950520 Notice not published Printed on acid-free paper